1-year follow-up study finds paclitaxel-coated balloons superior for in-stent restenosis prevention.

The AGENT IDE study, involving 600 patients with in-stent restenosis, found that paclitaxel-coated balloons were superior to uncoated balloons in preventing target lesion failure at one-year follow-up. The drug-coated balloon offers an effective treatment strategy for managing coronary in-stent restenosis and is the first coronary drug-coated balloon to be approved in the United States.

March 09, 2024
5 Articles

Further Reading